Genomic and epigenomic alterations in prostate cancer

Frontiers in Endocrinology

Volumn 3, Issue NOV, 2012, Pages

  Aschelter, Anna M ^a   Giacinti, Silvana ^a   Caporello, Paola ^a   Marchetti, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Prostate cancer

Indexed keywords

EID: 84874435605     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00128     Document Type: Review

References (81)

1. Agus, D. B., Akita, R. W., Fox, W. D. Lewis, G. D., Higgins, B., Pisacane, P. I., etal. (2002). Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2,127-137.
2. American Cancer Society. (2012). Cancer Facts & Figures 2012. Atlanta: American Cancer Society.
3. Araujo, L, Armstrong, A. L, Braud, E. L., Posadas, E., Lonberg, M., Gal-lick, G. E., etal. (2009). Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: a phase I/II study (CA180086)./. Clin. Oncol. 27(SUPPL.), 249s, abstr. 5061.
4. Bander, N. H., Milowsky, M. I., Nanus, D. M., Kostakoglu, L., Vallabhajosula, S., and Goldsmith, S. 1. (2005). Phase I trial of 177Lutetium-labeled 1591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. Cancer 23, 4591-4601.
5. Berger, S., Kouzarides, T., Shiekhattar, R., and Shilatifard, A. (2009). An operational definition of epigenetics. Genes Dev. 23,781-783.
6. Cairns, P., Okami, K., Halachmi, S., Halachmi, N., Esteller, M., Herman,J G., etal. (1997). Frequent inac-tivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 57, 4997-5000.
7. Canil, C. M., Moore, M, Win-quist, E., Baetz, T., Pollak, M., Chi, K. N., etal. (2005). Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. Clin. Oncol. 23, 455-460.
8. Chi, K. N., Hotte, S. I., Yu, E., Tu, D., Eigl, B., Tannock, I., etal. (2009). Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. Clin. Oncol. 27(SUPPL.), 238s, abstr. 5012.
9. Chin, S. P., Dickinson, I. L., and Holloway, A. F. (2011). Epigenetic regulation of prostate cancer. Clin. Epigenet. 2,151-169.
10. Craft, N., Shostak, Y. Carey, M., and Sawyers, C. L. (1999). A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/ neu tyrosine kinase. Nat. Med. 5, 280-285.
11. Crawford, E. D. (1992). Challenges in the management of prostate carcinoma. Br. I Urol. 70(SUPPL. 1), 33-38.
12. Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C, Trapman, I., Hittmair, A., etal. (1994). Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54, 5474-5478.
13. De Bono, I., Bellmunt, I., Attard, G., Droz, I. P., Miller, K., Flechon, A., etal. (2007). An open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. Clin. Oncol. 25, 257-262.
14. De Bono, I. S., Logothetis, C. I., Molina, A., Fizazi, K., North, S., Chu, L, et al. (2011). Abiraterone and increased survival in metastatic prostate cancer. N. Engl.]. Med. 364, 1995-2005.
15. De Bono, I. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, I. P., Kocak, I., etal. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 376,1147-1154.
16. Dreicer, R., Agus, D. B., Mac Vicar, G. R., MacLean, D., Zhang, T., Stadler, W. M., etal. (2010). Safety, phar-macokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: a phase I/II, open-label study./. Clin. Oncol. 28(SUPPL.), 18s, abstr. 3084.
17. Feldman, B. I., and Feldman, D. (2001). The development of androgen-independent prostate cancer. Nature 34,1.
18. Ferlay, I., Shin, H. R., Bray, E, For-man, D., Mathers, C, and Parkin, D. M. (2010). GLOBOCAN2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Case No. 10 [Internet]. Lyon: International Agency for Research on Cancer. Available at: http://globocan.iarc.fr
19. Gao, X., Loggie, B. W., and Newaz, Z. (2002). The roles of sex steroid receptor coregulators in cancer. Mol. Cancer 1, 7.
20. Gernone, A., Pagliarulo, A., Tra-bucco, S., and Pagliarulo, V. (2011). Correlation between HER2 status and central nervous system (CNS) involvement in metastatic castration-resistant prostate cancer (mCRPC). Clin. Oncol. 29(SUPPL.), abstr. el5190.
21. Gravis, G., Goncalves, A., Bladou, F., Salem, N., Esterni, B., Bagattini, S.,etal. (2006). "A phase II study of erlotinib in advanced prostate cancer" in American Society of Clinical Oncology-Prostate Cancer Symposium 2006, February 24-26,2006, San Francisco, California, abstr. 216
22. Gregory, C. W., Johnson, R. T. Ir., Mohler, J. L., French, F. S., Wilson, E. M., etal. (2004). Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensi-tivity to low androgen. Cancer Res. 61, 2892-2898.
23. Gross, M., Higano, C, Pantuck, A., Castellanos, O., Green, E., Nguyen, K., etal. (2007). A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 7, 142. doi: 10.1186/1471-2407-7-142
24. Gu, K., Mes Masson, A. M., Gauthier, I., and Saad, F. (1998). Analysis of the pl6 tumor suppressor gene in early-stage prostate cancer. Mol. Carcinog. 21,164-170.
25. Helcomb, I. N., Young, I. M., Cole-man, I. M., Salari, K., Grove, D. I., Hsu, L., etal. (2009). Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res. 69,7793-7802.
26. Hobisch, A., Culig, Z., Radmayr, C, Bartsch, G., Klocker, H., and Hittmair, A. (1995). Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res. 55, 3068-3072.
27. Huggins, C, and Hodges, C. V. (2002). Studies on prostatic cancer: the effect of castration, of estrogen and of androgen injection on serum phos-phatases in metastatic carcinoma of the prostate. 1941. Urol. 168, 9-12.
28. Hulett, M. D., Freeman, C, Hamdorf, B I., Baker, R. T., Harris, M. I., and Parish, C. R. (1999). Cloning of mammalian heparanase, an impor tant enzyme in tumor invasion and metastasis. Nat. Med. 5, 803-809.
29. Isambert, N., Freyer, G., Zanetta, S., Falandry, C, Soussan Lazard, K., Fumoleau, P., etal. (2008). A phase I dose escalation and pharmacokinetic (PK) study of intravenous afliber-cept (VEGF trap) plus docetaxel in patients with advanced solid tumors: preliminary results. Clin. Oncol. 26(SUPPL.), 177s, abstr. 3599.
30. Jarrard, D. F., Bova, I. S., Ewing, C M., Pin, S. S., Nguyen, S. H., Baylin, S. B., etal. (1997). Dele-tional, mutational, and methyla-tion analyses of CDKN2 (pl6/MTSl) in primary and metastatic prostate cancer. Genes Chromosomes Cancer 19, 90-96.
31. Kang, G. H., Lee, S., Lee, H. I., and Hwang, K. S. (2004). Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J. Pathol. 64, 1975-1986.
32. Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. I., Penson, D. E, etal. (2010a). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363,411-422.
33. Kantoff, P. W., Schuetz, T. I., Blumenstein, B. A., Glode, L. M., Bilhartz, D. L., Wyand M., etal. (2010b). Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. Clin. Oncol. 28, 1099-1105.
34. Kawashima, H., Takano, H., Sugita, S., Sugimura, K., and Nakatani, T. (2002). A novel steroid receptor co-activator protein (SRAP) as an alternative form of steroid receptor RNA-activator gene: expression in prostate cancer cells and enhancement of androgen receptor activity. Biochem. 369(Pt 1), 163-171.
35. Kelly, W. K., and Scher, H. I. (1993). Prostate specific antigen decline after antiandrogen withdrawal: the flu-tamide withdrawal syndrome. Urol. 149, 607-609.
36. Koivisto, P., Kononen, I., Palmberg, C, Tammela, T., Hyytinen, E., Isola, I., etal. (1997). Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 57,314-319.
37. Labrie, F. (2004). Adrenal androgens and intracrinology. Semin. Reprod. Med. 22, 299-309.
38. Labrie, F., Dupont, A., Belanger, A., St-Arnaud, R., Giguere, M., Lacour-ciere, Y., etal. (1986). Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr. Rev. 7, 67-74.
39. Lara, P. N. Ir., Chee, K. G., Long-mate, I., Ruel, C, Meyers, F. I., Gray, C. R., etal. (2004). Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 100,2125-2131.
40. Lee, W. H., Morton, R. A., Epstein, 1.1., Brooks, I. D., Campbell, P. A., Bova, G. S., etal. (1994). Cytidine methy-lation of regulatory sequences near the pi-class glutathione s-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 91, 11733-11737.
41. Li, L. C, Zhao, H., Nakajima, K., Oh, B. R., Ribeiro Filhho, L. A., and Carroll, P. (2001). Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer. Urol. 166,705-709.
42. Liu, I., Geller, I., Albert, I., and Kirshner, M. (1985). Acute effects of testicu-lar and adrenal cortical blockade on protein synthesis and dihydrotestos-terone content of human prostate tissue. Clin. Endocrinol. Metab. 61, 129-133.
43. Locke, I. A., Guns, E. S., Lubik, A. A., Adomat, H. H., Hendy, S. C, Wood, C. A., etal. (2008). Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68, 6407-6415.
44. Lonergan, P. E., and Tindall, D. I. (2011). Androgen receptor signaling in prostate cancer development, and progression. Carcinog. 10,20.
45. Mackinnon, A. C, Yan, B. C, joseph, L. I., Al-Ahmadie, H. A., etal. (2009). Molecular biology underlying the clinical heterogeneity of prostate cancer. Arch. Pathol. Lab. Med. 133, 1033-1040.
46. Makridakis, N., Ross, R. K., Pike, M. C, Chang, L., Stanczyk, F. Z., Kolonel, L. N.,etal. (1997).Aprevalentmissense substitution that modulates activity of prostatic steroid 5a-reductase. Cancer Res. 57, 1020-1022.
47. Marcelli, M., Ittmann, M., Mariani, S., Sutherland, R., Nigam, R., Murthy, L., etal. (2000). Androgen receptor mutations in prostate cancer. Cancer Res. 60, 944-949.
48. Mellinghoff, I. K., Vivanco, I., Kwon, A., Tran, C, Wongvipat, I., Sawyers, C. L, etal. (2004). HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6,517-527.
49. Milowsky, M. I., Nanus, D. M., Kostakoglu, L., Vallabhajosula, S., Goldsmith, S. I., and Bander, N. H. (2004). Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody 1591 for androgen-independent prostate cancer. Clin. Oncol. 22, 2522-2531.
50. Miyamoto, H., Yeh, S., Wilding, G., and Chang, C. (1998). Promotion of agonist activity of antiandrogens by the androgen receptor coactiva-tor, ARA70, in human prostate cancer DU145 cells. Proc. Natl. Acad. Sci. U.S.A. 95, 7379-7384.
51. Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. E, Higano, C. S., etal. (2008). Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism of castration-resistant tumor growth. Cancer Res. 68,4447-4454.
52. Nakayama, M., Bennett, C. I., Hicks, I. L, Epstein, I. I., Platz, E. A., Nelson, W G., etal. (2003). Hypermethylation of the human glutathione 5-transferase-jr gene (GSTP1) CpG island is present in a subset of prolif-erative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdis-section. Am. Pathol. 163, 923-933.
53. Nelson, W G., Carter, B., DeWeese, T. L., and Eisenberger, M. A. (2008). "Prostate cancer," in Clinical Oncology, 4th Edn., Vol. 2, eds M. D. Abeloff, I. O. Armitage, A. S. Lichter, I. E. Niederhuber, M. B. Kastan, and W. G. McKenna (Philadelphia, PA: Elsevier), 1656-1657.
54. Pakneshan, P., Xing, R., and Rabbani, S. (2003). Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. FASEBJ. 17,1081-1088.
55. Palmberg, C, Koivisto, P., Kakkola, L., Tammela, T. L., Kallioniemi, O. P., and Visakorpi, T. (2000).Androgen receptor gene amplification at primary progression predict response to combined androgen blockade as second line therapy for advanced prostate cancer. Urol. 164, 1992-1995.
56. Pasquali, D., Rossi, V., Staibano, S., De Rosa, G., Chieffi, P., Prezioso, D., etal. (2006). The endocrine-gland-derived vascular endothelial growth factor (EG-VEGF)/prokineticin 1 and 2 and receptor expression in human prostate: up-regulation of EG-VEGF/prokineticin 1 with malignancy. Endocrinology 147, 4245-4251.
57. Ruijter, E., van de Kaa, C, Miller, G., Ruiter, D., Debruyne, E, and Schalken, I. (1999). Molecular genetics and epidemiology of prostate carcinoma. Endocr. Rev. 20, 22-45.
58. Salzberg, M., Rochlitz, C, Morant, R., Thalmann, G., Pedrazzini, A., Rog-gero, E., etal. (2007). An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Onkologie 30,355-360.
59. Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M. E., Efstathiou, E., etal. (2010). Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375, 1437-1446
60. Signoretti, S., Montironi, R., Manola, J., Altimari, A., Tarn, C, Bubley, G., etal. (2000). Her-2-neu expression and progression toward andro-gen independence in human prostate cancer. Natl. Cancer Inst. 92, 1918-1925.
61. Small, E. J., and Srinivas, S. (1995). The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 76, 1428-1434.
62. Solit, D. B., and Rosen, N. (2007). Targeting HER2 in prostate cancer: where to next? J. Clin. Oncol. 25, 241-243.
63. Steers, W. D. (2001). 5alpha-reductase activity in the prostate. Urology 58(SUPPL. 1), 17-24.
64. Suzuki, H., Freije, D., Nusskern, D. R., Okami, K., Cairns, P., Sidransky, D., etal. (1998). Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 58, 204-209.
65. Suzuki, H., Ueda, T., Ichikawa, T., and Ito, H. (2003). Androgen receptor involvement in the progression of prostate cancer. Endocr. Relat. Cancer 10,209-216.
66. Tagawa, S. T., Beltran, H., Val-labhajosula, S., Goldsmith, S. J., Osborne, J., Matulich, D., etal. (2010). Anti-prostate-specific membrane antigen-based radioim-munotherapy for prostate cancer. Cancer 116, 1075-1083.
67. Tagawa, S. T., Milowsky, M. I., Morris, M., Vallabhajosula, S., Goldsmith, S., Matulich, D., etal. (2008). Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC). Clin. Oncol. 26(SUPPL.),284s.
68. Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., etal. (1995). Mutation of the, androgen receptor gene in metastatic, androgen-independent prostate cancer. N. Engl. J. Med. 332, 1393-1398.
69. Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., etal. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22.
70. Tekur, S., Lau, K. M., Long, J., Burnstein, K., and Ho, S. M. (2001). Expression of RFG/ELE I alpha/ARA70 in normal and malignant prostatic epithelial cell cultures and lines: regulation by methylation and sex steroids. Mol. Carcinog. 30, 1-13.
71. Titus, M. A., Gregory, C. W., Ford, O. H. III, Schell, M. J., Maygarden, S. J., and Mohler, J. L. (2005). Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin. Cancer Res. 11,4365-4371.
72. Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X. W., etal. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648.
73. Trachtenberg, J. J., and Pont, A. A. (1984). Ketoconazole therapy for advanced prostate cancer. Lancet 2, 433-435.
74. van der Kast, T. H., Schalken, J., Ruizeveld de Winter, J. A., van Vroonhoven, C. C, Mulder, E., Boersma, W.,etal. (1991). Androgen receptor in endocrine therapy resistant human prostate cancer. Int. J. Cancer 48,189-193.
75. Wang, E, Zou, Y. E, Feng, X. L, Su, H., and Huang, F. (2011). CYP17 gene polymorphisms and prostate cancer risk: a meta-analysis based on 38 independent studies. Prostate 71, 1167-1177.
76. Wen, Y, Hu, M. C, Makino, K., Spohn, B., Bartholomeusz, G., Yan, D. H., etal. (2000). HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 60, 6841-6845.
77. Wright, J. L, Kwon, E. M., Lin, D. W, Kolb, S., Koopmeiners, J. S., Feng, Z., etal. (2010). CYP17 polymorphisms and prostate cancer outcomes. Prostate 70, 1094-1101.
78. Yamaoka, M., Hara, T., Hitaka, T., Kaku, T., Takeuchi, T., Takahashi, J., etal. (2012). Orteronel (TAK-700),anovel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. Steroid Biochem. Mol. Biol. 129, 115-128.
79. Yeh, S., Lin, H. K., Kang, H. Y, Thin, T. H., Lin, M. E, and Chang, C. (1999). From HER2/Neu signal cascade to androgen receptor and its coactiva-tors: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. U.S.A. 96, 5458-5463.
80. Zhao, X. Y, Malloy, P. J., Krish-nan, A. V., Swami, S., Navone, N. M., Peehl, D. M., etal. (2000). Glucocorticoids can promote androgen independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med. 6, 703-706.
81. Ziada, A., Barqawi, A., Glode, L. M., Varella-Garcia, M., Crighton, E, Majeski, S., etal. (2004). The use of trastuzumab in the treatment of hormone refractory prostate cancer: phase II trial. Prostate 60, 332-337.